Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (ab205340)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [mOC23] to beta Amyloid - Conformation-Specific
- Suitable for: IHC-P, Dot blot
- Reacts with: Human, Recombinant fragment
Overview
-
Product name
Anti-beta Amyloid antibody [mOC23] - Conformation-Specific
See all beta Amyloid primary antibodies -
Description
Rabbit monoclonal [mOC23] to beta Amyloid - Conformation-Specific -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species IHC-P HumanWB Mouse -
Immunogen
Other Immunogen Type corresponding to Human beta Amyloid. (Amyloid beta 1-42 fibrils).
Database link: P05067 -
Positive control
- Dot Blot: beta Amyloid (Aß) 1-40; beta Amyloid (Aß) 1-42. IHC-P: FFPE Hu Brain Alzheimer
-
General notes
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab205340 (mOC23) recognizes an aggregation-dependent epitope of Aß that maps to a linear segment of Aß (residues 2-6, AEFRH) (Hatami et al 2014). mOC23 stains a subset of plaques, but weakly stains the central core of cored plaques. mOC23 also stains misfolded or aggregated intraneuronal amyloid deposits (Hatami et al 2014). Immunoreactivity on western blots is decreased by boiling the membrane.
For further information on the immunogen, please refer to Hatami et al. 2014 and Kayed et al. 2007.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
mOC23 -
Isotype
IgG -
Research areas
Images
-
IHC image of beta Amyloid staining in Human Brain Alzheimer formalin fixed paraffin embedded tissue section*, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab205340, 0.1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
-
Dot blot analysis of beta Amyloid labeled with ab205340 at 1/6000 dilution.
Lane 1: beta Amyloid (Aβ) 1-40;
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/30000 was used as secondary antibody.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.
Note: Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab205340:
Monomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 1% SDS and boiled for five minutes.
Oligomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils: 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.
-
Negative control (secondary ab only) Dot blot analysis of beta Amyloid.
Lane 1: beta Amyloid (Aβ) 1-40;
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/30000 was used as secondary antibody.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.
-